

HR 4832

Prescription Drug Comparative Effectiveness Act of 2002

Congress: 107 (2001–2003, Ended)

Chamber: House

Policy Area: Health

Introduced: May 23, 2002

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Jun 3, 2002)

Official Text: <https://www.congress.gov/bill/107th-congress/house-bill/4832>

Sponsor

Name: Rep. Allen, Thomas H. [D-ME-1]

Party: Democratic • **State:** ME • **Chamber:** House

Cosponsors (19 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Baldacci, John Elias [D-ME-2]	D · ME		May 23, 2002
Rep. Berry, Marion [D-AR-1]	D · AR		May 23, 2002
Rep. Brown, Sherrod [D-OH-13]	D · OH		May 23, 2002
Rep. DeLauro, Rosa L. [D-CT-3]	D · CT		May 23, 2002
Rep. Kaptur, Marcy [D-OH-9]	D · OH		May 23, 2002
Rep. Langevin, James R. [D-RI-2]	D · RI		May 23, 2002
Rep. Rangel, Charles B. [D-NY-15]	D · NY		May 23, 2002
Rep. Stark, Fortney Pete [D-CA-13]	D · CA		May 23, 2002
Rep. Waxman, Henry A. [D-CA-29]	D · CA		May 23, 2002
Rep. Barrett, Thomas M. [D-WI-5]	D · WI		Jun 6, 2002
Rep. Frost, Martin [D-TX-24]	D · TX		Jun 6, 2002
Rep. Gephardt, Richard A. [D-MO-3]	D · MO		Jun 6, 2002
Rep. Sandlin, Max [D-TX-1]	D · TX		Jun 6, 2002
Rep. Tierney, John F. [D-MA-6]	D · MA		Jun 6, 2002
Del. Norton, Eleanor Holmes [D-DC-At Large]	D · DC		Jun 20, 2002
Rep. Bonior, David E. [D-MI-10]	D · MI		Jun 20, 2002
Rep. Thurman, Karen L. [D-FL-5]	D · FL		Jun 20, 2002
Rep. Slaughter, Louise McIntosh [D-NY-28]	D · NY		Jul 9, 2002
Rep. Miller, George [D-CA-7]	D · CA		Sep 18, 2002

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Jun 3, 2002

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of May 23, 2002)

Prescription Drug Comparative Effectiveness Act of 2002 - Directs the Director of the Agency for Healthcare Research and Quality to study, analyze, and report to Congress on valid scientific evidence regarding the comparative effectiveness and cost-effectiveness, relative to other drugs and treatments, of prescription drugs that account for high levels of expenditures or use by individuals entitled to benefits under titles XVIII (Medicare) or XIX (Medicaid) of the Social Security Act.

Actions Timeline

- **Jun 3, 2002:** Referred to the Subcommittee on Health.
- **May 23, 2002:** Introduced in House
- **May 23, 2002:** Introduced in House
- **May 23, 2002:** Referred to the House Committee on Energy and Commerce.